Apollomics, Inc.

49 articles with Apollomics, Inc.

• 

  How COVID-19 is Affecting Clinical Trials and Drug Supplies from Biotech Bay Companies

  6/5/2020

  Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.

• Apollomics, Inc. Announces Initiation of SPARTA Phase 2 Clinical Trial for c-MET Inhibitor APL-101

  5/21/2020

  Focus on non-small cell lung cancer with a mutation that leads to MET exon 14 skipping, and tumors with amplifications and MET fusions, including glioblastoma multiforme

• GlycoMimetics and Apollomics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Uproleselan and GMI-1687 in Greater China

  1/6/2020

  GlycoMimetics to receive an upfront cash payment with eligibility to receive development, regulatory, and sales-based milestones, and tiered royalties

• 

  BioSpace Movers and Shakers: May 3

  5/3/2019

  Biopharma companies make changes to their C-suite leadership teams, with hires at uBiome, Enzyre, Sobi, Amylyx, Mission Therapeutics, and more.

• Apollomics, Inc. Appoints Fabio M. Benedetti, M.D. as Chief Medical Officer

  5/1/2019

  Apollomics, Inc. announced that Fabio M. Benedetti, M.D. has joined the senior leadership team as Chief Medical Officer (CMO).

• Apollomics, Inc. Presents Positive Preclinical Data on APL-102, an oral Multi-Kinase Inhibitor with CSF-1R Activity

  4/1/2019

  Activity Demonstrated as a Single Agent and in Combination with an anti-PD-1 antibody

• Apollomics, Inc. Strengthens Leadership with Key Hires

  1/16/2019

  Wilson W. Cheung, CPA appointed Chief Financial Officer

• Apollomics, Inc. (previously CBT Pharmaceuticals, Inc.) Raises $100 Million in Series B Financing

  1/7/2019

  Financing will accelerate development of the Company’s cancer immunotherapy and targeted therapy programs

• CBT Pharmaceuticals and Strata Oncology Announce Collaboration to Accelerate Development of CBT-101, a c-Met inhibitor, for Patients with Non-Small Cell Lung Cancer and other Solid Tumors

  12/10/2018

  Strata will exclusively refer Met-amplified, Met-mutation and Met-fusion advanced cancer patients identified through the Strata Trial for enrollment consideration into CBT's clinical development program for CBT-101.

• CBT Pharmaceuticals and Zhejiang Bossan Pharmaceutical Enter into a Collaboration and License Agreement to Develop Combination Cancer Treatments

  11/26/2018

  CBT’s c-Met inhibitor and anti-PD1 antibody to be evaluated in combination with Bossan’s EGFR inhibitor

• CBT Pharmaceuticals Awarded NIH Small Business Innovation Research Grant Towards Development of Combination Checkpoint Inhibition

  10/15/2018

  CBT Pharmaceuticals today announced it has been awarded a Small Business Innovation Research (SBIR) Grant from the U.S. Department of Health and Human Services National Cancer Institute (NCI) of the National Institutes of Health (NIH). 

• First Patient Dosed in Initial Immunotherapy Combination Trial Utilizing CBT’s Proprietary Assets

  9/19/2018

  CBT Pharmaceuticalstoday announced the initiation of the APOLLO Oncology Clinical Trials Program.

• CBT Pharmaceuticals Strengthens Management Team with the Appointment of Yuling Li, PhD as Senior Vice President, Process Development and Manufacturing

  8/16/2018

  CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies, today announced a new global leadership structure and the appointment of Yuling Li, PhD as Senior Vice President, Process Development and Manufacturing.

• CBT Pharmaceuticals Receives First Australian Ethics Approval to Initiate APOLLO-1 Phase 1/2 Clinical Trial for Hepatocellular and Renal Cell Carcinoma

  8/8/2018

  CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies, today announced the receipt of ethics approval from the Bellberry Human Research Ethics Committee (HREC) in Australia for its planned APOLLO-1 clinical trial.

• CBT Pharmaceuticals Initiates Phase 1b Clinical Trial for Anti-PD-1 Antibody CBT-501-01 (genolimzumab injection) in Patients with Advanced Solid Tumors

  7/26/2018

  CBT Pharmaceuticals today announced the continuation of the CBT-501 Phase 1 clinical trial with the initiation of the Phase 1b segment of the study in patients with select advanced or relapsed/recurrent solid tumors.

• CBT Pharmaceuticals and CrystalGenomics Announce Partnership for Co-development of Global Immuno-Oncology Therapy

  4/23/2018

  CBT Pharmaceuticals (CBT) and CrystalGenomics, Inc., (KOSDAQ:083790) today announced a co-development agreement for an investigational combination therapy of CBT-501 and CG200745 across a variety of solid tumors with high unmet medical needs.

• 

  AACR Meeting Brief: Compugen, Bayer, Tarveda, Alligator and Others

  4/17/2018

  Now in its fourth day, the American Association of Cancer Research (AACR) Annual Meeting 2018 held in Chicago, has had plenty of news, much of it preclinical or early-clinical data.

• CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of Its Multi-Tyrosine Kinase Inhibitor, CBT-102, at AACR Annual Meeting 2018

  4/17/2018

  CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies, presented preclinical in-vivo data and animal safety pharmacology studies of CBT-102

• CBT Pharmaceuticals to Grow Immuno-Oncology Pipeline by License Agreement of CrownBio CTLA-4 Antibody

  3/23/2018

  Crown Bioscience and a global drug discovery and development services company announced a strategic licensing agreement with CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company.

• 

  What You Need to Know About CBT Pharmaceuticals

  1/12/2018

  Based in Santa Clara, California, CBT Pharma was spun out of Crown Bioscience with four development-stage assets in the oncology space.